context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. | text | 2569839 | sharesItemType | text: <entity> 2569839 </entity> <entity type> sharesItemType </entity type> <context> Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. </context> | us-gaap:TreasuryStockSharesAcquired |
Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. | text | 299443 | sharesItemType | text: <entity> 299443 </entity> <entity type> sharesItemType </entity type> <context> Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. </context> | us-gaap:TreasuryStockSharesAcquired |
Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. | text | 2869282 | sharesItemType | text: <entity> 2869282 </entity> <entity type> sharesItemType </entity type> <context> Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. </context> | us-gaap:TreasuryStockSharesAcquired |
Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. | text | 174.26 | perShareItemType | text: <entity> 174.26 </entity> <entity type> perShareItemType </entity type> <context> Under the terms of the 2024 ASR Agreement, the Company paid Citibank $ 500,000 on March 1, 2024 and on that date received initial delivery of 2,569,839 shares, representing a substantial majority of the shares expected to be retired over the course of the 2024 ASR Program. In July 2024, Citibank delivered 299,443 additional shares which completed the 2024 ASR Program totaling 2,869,282 repurchased shares. The total number of shares ultimately repurchased under the 2024 ASR Program was based on the volume-weighted average share price of Dover's common stock during the calculation period of the 2024 ASR Program, less a discount, which was $ 174.26 over the term of the ASR Program. </context> | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
During the years ended December 31, 2024, and 2023, exclusive of any ASR Programs, there were no share repurchases. During the year ended 2022, exclusive of the 2022 ASR Program, the Company repurchased 641,428 shares of common stock at a total cost of $ 85,000 or $ 132.52 per share. | text | 641428 | sharesItemType | text: <entity> 641428 </entity> <entity type> sharesItemType </entity type> <context> During the years ended December 31, 2024, and 2023, exclusive of any ASR Programs, there were no share repurchases. During the year ended 2022, exclusive of the 2022 ASR Program, the Company repurchased 641,428 shares of common stock at a total cost of $ 85,000 or $ 132.52 per share. </context> | us-gaap:TreasuryStockSharesAcquired |
During the years ended December 31, 2024, and 2023, exclusive of any ASR Programs, there were no share repurchases. During the year ended 2022, exclusive of the 2022 ASR Program, the Company repurchased 641,428 shares of common stock at a total cost of $ 85,000 or $ 132.52 per share. | text | 85000 | monetaryItemType | text: <entity> 85000 </entity> <entity type> monetaryItemType </entity type> <context> During the years ended December 31, 2024, and 2023, exclusive of any ASR Programs, there were no share repurchases. During the year ended 2022, exclusive of the 2022 ASR Program, the Company repurchased 641,428 shares of common stock at a total cost of $ 85,000 or $ 132.52 per share. </context> | us-gaap:PaymentsForRepurchaseOfCommonStock |
During the years ended December 31, 2024, and 2023, exclusive of any ASR Programs, there were no share repurchases. During the year ended 2022, exclusive of the 2022 ASR Program, the Company repurchased 641,428 shares of common stock at a total cost of $ 85,000 or $ 132.52 per share. | text | 132.52 | perShareItemType | text: <entity> 132.52 </entity> <entity type> perShareItemType </entity type> <context> During the years ended December 31, 2024, and 2023, exclusive of any ASR Programs, there were no share repurchases. During the year ended 2022, exclusive of the 2022 ASR Program, the Company repurchased 641,428 shares of common stock at a total cost of $ 85,000 or $ 132.52 per share. </context> | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
As of December 31, 2024, 17,130,718 shares remain authorized for repurchase under the August 2023 share repurchase authorization. | text | 17130718 | sharesItemType | text: <entity> 17130718 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, 17,130,718 shares remain authorized for repurchase under the August 2023 share repurchase authorization. </context> | us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased |
Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The allowance for doubtful accounts was $ 0.1 million and $ 0.1 million as of December 31, 2024 and 2023, respectively. | text | 0.1 | monetaryItemType | text: <entity> 0.1 </entity> <entity type> monetaryItemType </entity type> <context> Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The allowance for doubtful accounts was $ 0.1 million and $ 0.1 million as of December 31, 2024 and 2023, respectively. </context> | us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent |
The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. The Company recorded impairment charges of $ 3.1 million and $ 9.8 million primarily relating to computer equipment, software, right-of-use assets, and intangible assets during the years ended December 31, 2024 and 2023, respectively. There were no impairment losses recorded for the year ended December 31, 2022. Refer to Note 5, Other Financial Statement Information | text | 3.1 | monetaryItemType | text: <entity> 3.1 </entity> <entity type> monetaryItemType </entity type> <context> The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. The Company recorded impairment charges of $ 3.1 million and $ 9.8 million primarily relating to computer equipment, software, right-of-use assets, and intangible assets during the years ended December 31, 2024 and 2023, respectively. There were no impairment losses recorded for the year ended December 31, 2022. Refer to Note 5, Other Financial Statement Information </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. The Company recorded impairment charges of $ 3.1 million and $ 9.8 million primarily relating to computer equipment, software, right-of-use assets, and intangible assets during the years ended December 31, 2024 and 2023, respectively. There were no impairment losses recorded for the year ended December 31, 2022. Refer to Note 5, Other Financial Statement Information | text | 9.8 | monetaryItemType | text: <entity> 9.8 </entity> <entity type> monetaryItemType </entity type> <context> The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. The Company recorded impairment charges of $ 3.1 million and $ 9.8 million primarily relating to computer equipment, software, right-of-use assets, and intangible assets during the years ended December 31, 2024 and 2023, respectively. There were no impairment losses recorded for the year ended December 31, 2022. Refer to Note 5, Other Financial Statement Information </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. The Company recorded impairment charges of $ 3.1 million and $ 9.8 million primarily relating to computer equipment, software, right-of-use assets, and intangible assets during the years ended December 31, 2024 and 2023, respectively. There were no impairment losses recorded for the year ended December 31, 2022. Refer to Note 5, Other Financial Statement Information | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. The Company recorded impairment charges of $ 3.1 million and $ 9.8 million primarily relating to computer equipment, software, right-of-use assets, and intangible assets during the years ended December 31, 2024 and 2023, respectively. There were no impairment losses recorded for the year ended December 31, 2022. Refer to Note 5, Other Financial Statement Information </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
Advertising costs are expensed as incurred. The Company incurred advertising costs of $ 3.9 million, $ 3.3 million and $ 3.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Advertising costs are expensed as incurred. The Company incurred advertising costs of $ 3.9 million, $ 3.3 million and $ 3.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:AdvertisingExpense |
Advertising costs are expensed as incurred. The Company incurred advertising costs of $ 3.9 million, $ 3.3 million and $ 3.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> Advertising costs are expensed as incurred. The Company incurred advertising costs of $ 3.9 million, $ 3.3 million and $ 3.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:AdvertisingExpense |
Advertising costs are expensed as incurred. The Company incurred advertising costs of $ 3.9 million, $ 3.3 million and $ 3.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. | text | 3.7 | monetaryItemType | text: <entity> 3.7 </entity> <entity type> monetaryItemType </entity type> <context> Advertising costs are expensed as incurred. The Company incurred advertising costs of $ 3.9 million, $ 3.3 million and $ 3.7 million for the years ended December 31, 2024, 2023 and 2022, respectively. </context> | us-gaap:AdvertisingExpense |
For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in “Other expense, net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $ 2.1 million for the year ended December 31, 2024. The Company recognized foreign currency transaction gains of $ 1.2 million and $ 0.2 million for the years ended December 31, 2023 and 2022, respectively. | text | 2.1 | monetaryItemType | text: <entity> 2.1 </entity> <entity type> monetaryItemType </entity type> <context> For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in “Other expense, net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $ 2.1 million for the year ended December 31, 2024. The Company recognized foreign currency transaction gains of $ 1.2 million and $ 0.2 million for the years ended December 31, 2023 and 2022, respectively. </context> | us-gaap:ForeignCurrencyTransactionGainLossBeforeTax |
For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in “Other expense, net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $ 2.1 million for the year ended December 31, 2024. The Company recognized foreign currency transaction gains of $ 1.2 million and $ 0.2 million for the years ended December 31, 2023 and 2022, respectively. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in “Other expense, net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $ 2.1 million for the year ended December 31, 2024. The Company recognized foreign currency transaction gains of $ 1.2 million and $ 0.2 million for the years ended December 31, 2023 and 2022, respectively. </context> | us-gaap:ForeignCurrencyTransactionGainLossBeforeTax |
For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in “Other expense, net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $ 2.1 million for the year ended December 31, 2024. The Company recognized foreign currency transaction gains of $ 1.2 million and $ 0.2 million for the years ended December 31, 2023 and 2022, respectively. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are remeasured at historical exchange rates. Revenue and expenses are remeasured at the average exchange rates for the period. Gains or losses from foreign currency remeasurement are included in “Other expense, net” in the consolidated statements of operations. The Company recognized foreign currency transaction losses of $ 2.1 million for the year ended December 31, 2024. The Company recognized foreign currency transaction gains of $ 1.2 million and $ 0.2 million for the years ended December 31, 2023 and 2022, respectively. </context> | us-gaap:ForeignCurrencyTransactionGainLossBeforeTax |
On December 7, 2023, the Company committed to a restructuring plan related to the closure of one of its research and development facilities resulting in restructuring charges of $ 2.5 million associated with this plan, comprised primarily of long-lived assets impairment costs and one-time employee termination benefits which were recorded during the year ended December 31, 2023. Restructuring costs of $ 2.5 million were recorded in research and development and general and administrative expenses during the year ended December 31, 2023 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2024. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> On December 7, 2023, the Company committed to a restructuring plan related to the closure of one of its research and development facilities resulting in restructuring charges of $ 2.5 million associated with this plan, comprised primarily of long-lived assets impairment costs and one-time employee termination benefits which were recorded during the year ended December 31, 2023. Restructuring costs of $ 2.5 million were recorded in research and development and general and administrative expenses during the year ended December 31, 2023 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2024. </context> | us-gaap:RestructuringCosts |
On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. | text | 4.2 | monetaryItemType | text: <entity> 4.2 </entity> <entity type> monetaryItemType </entity type> <context> On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. </context> | us-gaap:RestructuringCosts |
On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. </context> | us-gaap:RestructuringCosts |
On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. </context> | us-gaap:RestructuringCosts |
On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. | text | 2.5 | monetaryItemType | text: <entity> 2.5 </entity> <entity type> monetaryItemType </entity type> <context> On August 3, 2022, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $ 4.2 million associated with this plan, comprised primarily of severance-related costs, were recorded during the year ended December 31, 2022. Restructuring costs of $ 0.3 million, $ 1.4 million and $ 2.5 million were recorded in cost of revenue, research and development expense, and selling, general and administrative expense, respectively, during the year ended December 31, 2022 in the Company's consolidated statements of operations. The restructuring activities were completed as of December 31, 2022. </context> | us-gaap:RestructuringCosts |
On January 28, 2023, the Company signed an agreement to acquire certain intangible and other assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. for an upfront cash payment of $ 10.0 million relating to an intellectual property license. Upon the close of the transaction on July 14, 2023, the Company paid additional cash consideration of $ 10.0 million upon acquiring the assets. Under the agreement, the Company is obligated to provide additional cash consideration if certain technology development milestones are met. As of December 31, 2023, the Company had paid $ 21.3 million relating to the completion of development milestones. The Company paid an additional $ 20.0 million in January 2024 in relation to a development milestone which was accrued in the Company's consolidated financial statements as of December 31, 2023. Up to $ 15.0 million of cash consideration is due if an additional technology development milestone is met. Furthermore, the Company expects to pay cash consideration tied to future sales milestones if such milestones are met. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> On January 28, 2023, the Company signed an agreement to acquire certain intangible and other assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. for an upfront cash payment of $ 10.0 million relating to an intellectual property license. Upon the close of the transaction on July 14, 2023, the Company paid additional cash consideration of $ 10.0 million upon acquiring the assets. Under the agreement, the Company is obligated to provide additional cash consideration if certain technology development milestones are met. As of December 31, 2023, the Company had paid $ 21.3 million relating to the completion of development milestones. The Company paid an additional $ 20.0 million in January 2024 in relation to a development milestone which was accrued in the Company's consolidated financial statements as of December 31, 2023. Up to $ 15.0 million of cash consideration is due if an additional technology development milestone is met. Furthermore, the Company expects to pay cash consideration tied to future sales milestones if such milestones are met. </context> | us-gaap:PaymentsToAcquireIntangibleAssets |
On January 28, 2023, the Company signed an agreement to acquire certain intangible and other assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. for an upfront cash payment of $ 10.0 million relating to an intellectual property license. Upon the close of the transaction on July 14, 2023, the Company paid additional cash consideration of $ 10.0 million upon acquiring the assets. Under the agreement, the Company is obligated to provide additional cash consideration if certain technology development milestones are met. As of December 31, 2023, the Company had paid $ 21.3 million relating to the completion of development milestones. The Company paid an additional $ 20.0 million in January 2024 in relation to a development milestone which was accrued in the Company's consolidated financial statements as of December 31, 2023. Up to $ 15.0 million of cash consideration is due if an additional technology development milestone is met. Furthermore, the Company expects to pay cash consideration tied to future sales milestones if such milestones are met. | text | 10.0 | monetaryItemType | text: <entity> 10.0 </entity> <entity type> monetaryItemType </entity type> <context> On January 28, 2023, the Company signed an agreement to acquire certain intangible and other assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. for an upfront cash payment of $ 10.0 million relating to an intellectual property license. Upon the close of the transaction on July 14, 2023, the Company paid additional cash consideration of $ 10.0 million upon acquiring the assets. Under the agreement, the Company is obligated to provide additional cash consideration if certain technology development milestones are met. As of December 31, 2023, the Company had paid $ 21.3 million relating to the completion of development milestones. The Company paid an additional $ 20.0 million in January 2024 in relation to a development milestone which was accrued in the Company's consolidated financial statements as of December 31, 2023. Up to $ 15.0 million of cash consideration is due if an additional technology development milestone is met. Furthermore, the Company expects to pay cash consideration tied to future sales milestones if such milestones are met. </context> | us-gaap:AssetAcquisitionConsiderationTransferred |
On January 28, 2023, the Company signed an agreement to acquire certain intangible and other assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. for an upfront cash payment of $ 10.0 million relating to an intellectual property license. Upon the close of the transaction on July 14, 2023, the Company paid additional cash consideration of $ 10.0 million upon acquiring the assets. Under the agreement, the Company is obligated to provide additional cash consideration if certain technology development milestones are met. As of December 31, 2023, the Company had paid $ 21.3 million relating to the completion of development milestones. The Company paid an additional $ 20.0 million in January 2024 in relation to a development milestone which was accrued in the Company's consolidated financial statements as of December 31, 2023. Up to $ 15.0 million of cash consideration is due if an additional technology development milestone is met. Furthermore, the Company expects to pay cash consideration tied to future sales milestones if such milestones are met. | text | 15.0 | monetaryItemType | text: <entity> 15.0 </entity> <entity type> monetaryItemType </entity type> <context> On January 28, 2023, the Company signed an agreement to acquire certain intangible and other assets from Centrillion Technologies, Inc. and Centrillion Technology Holdings Corp. for an upfront cash payment of $ 10.0 million relating to an intellectual property license. Upon the close of the transaction on July 14, 2023, the Company paid additional cash consideration of $ 10.0 million upon acquiring the assets. Under the agreement, the Company is obligated to provide additional cash consideration if certain technology development milestones are met. As of December 31, 2023, the Company had paid $ 21.3 million relating to the completion of development milestones. The Company paid an additional $ 20.0 million in January 2024 in relation to a development milestone which was accrued in the Company's consolidated financial statements as of December 31, 2023. Up to $ 15.0 million of cash consideration is due if an additional technology development milestone is met. Furthermore, the Company expects to pay cash consideration tied to future sales milestones if such milestones are met. </context> | us-gaap:AssetAcquisitionContingentConsiderationLiability |
The transaction was accounted for as an asset acquisition. In connection with this acquisition and milestone payments, the Company acquired an in-process research and development intangible asset of $ 61.0 million during the year ended December 31, 2023 which did not have alternative future use and therefore was recognized as an expense and included as a component of “In-process research and development” in the condensed consolidated statements of operations. The Company also acquired an intangible asset of $ 0.2 million related to assembled workforce which is included in “Intangible assets, net” in the consolidated balance sheets. | text | 61.0 | monetaryItemType | text: <entity> 61.0 </entity> <entity type> monetaryItemType </entity type> <context> The transaction was accounted for as an asset acquisition. In connection with this acquisition and milestone payments, the Company acquired an in-process research and development intangible asset of $ 61.0 million during the year ended December 31, 2023 which did not have alternative future use and therefore was recognized as an expense and included as a component of “In-process research and development” in the condensed consolidated statements of operations. The Company also acquired an intangible asset of $ 0.2 million related to assembled workforce which is included in “Intangible assets, net” in the consolidated balance sheets. </context> | us-gaap:IndefinitelivedIntangibleAssetsAcquired |
The transaction was accounted for as an asset acquisition. In connection with this acquisition and milestone payments, the Company acquired an in-process research and development intangible asset of $ 61.0 million during the year ended December 31, 2023 which did not have alternative future use and therefore was recognized as an expense and included as a component of “In-process research and development” in the condensed consolidated statements of operations. The Company also acquired an intangible asset of $ 0.2 million related to assembled workforce which is included in “Intangible assets, net” in the consolidated balance sheets. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> The transaction was accounted for as an asset acquisition. In connection with this acquisition and milestone payments, the Company acquired an in-process research and development intangible asset of $ 61.0 million during the year ended December 31, 2023 which did not have alternative future use and therefore was recognized as an expense and included as a component of “In-process research and development” in the condensed consolidated statements of operations. The Company also acquired an intangible asset of $ 0.2 million related to assembled workforce which is included in “Intangible assets, net” in the consolidated balance sheets. </context> | us-gaap:FinitelivedIntangibleAssetsAcquired1 |
The company incurred gross realized losses of $ 3.0 thousand and $ 1.7 million, from the sale of available-for-sales debt securities during the years ended December 31, 2024 and 2023, respectively. The Company incurred no material gross realized | text | 3.0 | monetaryItemType | text: <entity> 3.0 </entity> <entity type> monetaryItemType </entity type> <context> The company incurred gross realized losses of $ 3.0 thousand and $ 1.7 million, from the sale of available-for-sales debt securities during the years ended December 31, 2024 and 2023, respectively. The Company incurred no material gross realized </context> | us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss |
The company incurred gross realized losses of $ 3.0 thousand and $ 1.7 million, from the sale of available-for-sales debt securities during the years ended December 31, 2024 and 2023, respectively. The Company incurred no material gross realized | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> The company incurred gross realized losses of $ 3.0 thousand and $ 1.7 million, from the sale of available-for-sales debt securities during the years ended December 31, 2024 and 2023, respectively. The Company incurred no material gross realized </context> | us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss |
The company incurred gross realized losses of $ 3.0 thousand and $ 1.7 million, from the sale of available-for-sales debt securities during the years ended December 31, 2024 and 2023, respectively. The Company incurred no material gross realized | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> The company incurred gross realized losses of $ 3.0 thousand and $ 1.7 million, from the sale of available-for-sales debt securities during the years ended December 31, 2024 and 2023, respectively. The Company incurred no material gross realized </context> | us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss |
Depreciation expense was $ 33.9 million, $ 32.9 million and $ 22.8 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 33.9 | monetaryItemType | text: <entity> 33.9 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 33.9 million, $ 32.9 million and $ 22.8 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
Depreciation expense was $ 33.9 million, $ 32.9 million and $ 22.8 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 32.9 | monetaryItemType | text: <entity> 32.9 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 33.9 million, $ 32.9 million and $ 22.8 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
Depreciation expense was $ 33.9 million, $ 32.9 million and $ 22.8 million for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 22.8 | monetaryItemType | text: <entity> 22.8 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense was $ 33.9 million, $ 32.9 million and $ 22.8 million for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:Depreciation |
During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. | text | 2.1 | monetaryItemType | text: <entity> 2.1 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. | text | 0.7 | monetaryItemType | text: <entity> 0.7 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. | text | 1.1 | monetaryItemType | text: <entity> 1.1 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company recorded impairment charges of $ 2.1 million related to computer equipment and software of which $ 0.3 million, $ 0.7 million and $ 1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project. </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
During the year ended December 31, 2023, the Company recorded impairment charges of $ 4.6 million related to its developed technology and assembled workforce. No impairment losses were recognized for intangible assets during the years ended December 31, 2024 and December 31, 2022. | text | 4.6 | monetaryItemType | text: <entity> 4.6 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, the Company recorded impairment charges of $ 4.6 million related to its developed technology and assembled workforce. No impairment losses were recognized for intangible assets during the years ended December 31, 2024 and December 31, 2022. </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
During the year ended December 31, 2023, the Company recorded impairment charges of $ 4.6 million related to its developed technology and assembled workforce. No impairment losses were recognized for intangible assets during the years ended December 31, 2024 and December 31, 2022. | text | No | monetaryItemType | text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, the Company recorded impairment charges of $ 4.6 million related to its developed technology and assembled workforce. No impairment losses were recognized for intangible assets during the years ended December 31, 2024 and December 31, 2022. </context> | us-gaap:ImpairmentOfLongLivedAssetsHeldForUse |
As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. | text | 33.2 | monetaryItemType | text: <entity> 33.2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. </context> | us-gaap:RevenueRemainingPerformanceObligation |
As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. | text | 20.7 | monetaryItemType | text: <entity> 20.7 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. </context> | us-gaap:ContractWithCustomerLiabilityCurrent |
As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. | text | 33.2 | monetaryItemType | text: <entity> 33.2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. </context> | us-gaap:ContractWithCustomerLiability |
As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. | text | 22.0 | monetaryItemType | text: <entity> 22.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements, or allocated amounts for extended warranty service agreements bundled with sales of instruments, was $ 33.2 million, of which approximately $ 20.7 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of $ 33.2 million and $ 22.0 million as of December 31, 2024 and 2023, respectively, consisted of deferred revenue related to extended warranty service agreements. </context> | us-gaap:ContractWithCustomerLiability |
As of December 31, 2024 and 2023, the Company maintained a full valuation allowance on its U.S. net deferred tax assets. The U.S. deferred tax assets predominantly relate to operating losses, tax credits and capitalized R&D intangibles. The U.S. valuation allowance was estimated based on an assessment of both positive and negative evidence to determine whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses, required that a full valuation allowance be recorded against all U.S. net deferred tax assets. The Company intends to maintain a full valuation allowance on U.S. net deferred tax assets until sufficient positive evidence exists to support a reversal of the valuation allowance. The valuation allowance increased by $ 36.4 million and by $ 78.8 million for the years ended December 31, 2024 and 2023, respectively. | text | 36.4 | monetaryItemType | text: <entity> 36.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company maintained a full valuation allowance on its U.S. net deferred tax assets. The U.S. deferred tax assets predominantly relate to operating losses, tax credits and capitalized R&D intangibles. The U.S. valuation allowance was estimated based on an assessment of both positive and negative evidence to determine whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses, required that a full valuation allowance be recorded against all U.S. net deferred tax assets. The Company intends to maintain a full valuation allowance on U.S. net deferred tax assets until sufficient positive evidence exists to support a reversal of the valuation allowance. The valuation allowance increased by $ 36.4 million and by $ 78.8 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
As of December 31, 2024 and 2023, the Company maintained a full valuation allowance on its U.S. net deferred tax assets. The U.S. deferred tax assets predominantly relate to operating losses, tax credits and capitalized R&D intangibles. The U.S. valuation allowance was estimated based on an assessment of both positive and negative evidence to determine whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses, required that a full valuation allowance be recorded against all U.S. net deferred tax assets. The Company intends to maintain a full valuation allowance on U.S. net deferred tax assets until sufficient positive evidence exists to support a reversal of the valuation allowance. The valuation allowance increased by $ 36.4 million and by $ 78.8 million for the years ended December 31, 2024 and 2023, respectively. | text | 78.8 | monetaryItemType | text: <entity> 78.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, the Company maintained a full valuation allowance on its U.S. net deferred tax assets. The U.S. deferred tax assets predominantly relate to operating losses, tax credits and capitalized R&D intangibles. The U.S. valuation allowance was estimated based on an assessment of both positive and negative evidence to determine whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction basis. The Company’s history of cumulative losses, along with expected future U.S. losses, required that a full valuation allowance be recorded against all U.S. net deferred tax assets. The Company intends to maintain a full valuation allowance on U.S. net deferred tax assets until sufficient positive evidence exists to support a reversal of the valuation allowance. The valuation allowance increased by $ 36.4 million and by $ 78.8 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. | text | 638.7 | monetaryItemType | text: <entity> 638.7 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. | text | 88.5 | monetaryItemType | text: <entity> 88.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. </context> | us-gaap:TaxCreditCarryforwardAmount |
As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. | text | 632.9 | monetaryItemType | text: <entity> 632.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. | text | 424.5 | monetaryItemType | text: <entity> 424.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. | text | 68.3 | monetaryItemType | text: <entity> 68.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had federal net operating loss (NOL) carryforwards of $ 638.7 million and federal tax credit carryforwards of $ 88.5 million. The federal NOL carryforwards generated after December 31, 2017 totaling $ 632.9 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2033. As of December 31, 2024, the Company had state NOL carryforwards of $ 424.5 million, which begin to expire primarily in 2033. In addition, the Company had state tax credit carryforwards of $ 68.3 million, which do not expire. </context> | us-gaap:TaxCreditCarryforwardAmount |
The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. | text | 50.0 | monetaryItemType | text: <entity> 50.0 </entity> <entity type> monetaryItemType </entity type> <context> The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. </context> | us-gaap:UnrecognizedTaxBenefits |
The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. | text | 45.7 | monetaryItemType | text: <entity> 45.7 </entity> <entity type> monetaryItemType </entity type> <context> The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. </context> | us-gaap:UnrecognizedTaxBenefits |
The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. | text | 2.7 | monetaryItemType | text: <entity> 2.7 </entity> <entity type> monetaryItemType </entity type> <context> The total amount of unrecognized gross tax benefits was $ 50.0 million and $ 45.7 million as of December 31, 2024 and 2023, respectively, of which $ 2.9 million and $ 2.7 million, if recognized, would affect our effective tax rate, respectively. </context> | us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate |
The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. | text | 1.6 | monetaryItemType | text: <entity> 1.6 </entity> <entity type> monetaryItemType </entity type> <context> The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued |
The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. | text | 0.9 | monetaryItemType | text: <entity> 0.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued |
The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. | text | 0.7 | monetaryItemType | text: <entity> 0.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense |
The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense |
The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company includes interest and penalties related to income tax matters within the provision for income taxes. The total amount of gross interest and penalties accrued was $ 1.6 million and $ 0.9 million for the years ended December 31, 2024 and 2023, respectively. The Company recognized interest and penalty expenses of $ 0.7 million, $ 0.5 million and $ 0.2 million in 2024, 2023, and 2022, respectively. </context> | us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense |
Company’s behalf and cannot be used by their other customers, the Company is obligated to purchase these components. In addition, certain supplier agreements require the Company to make minimum annual purchases under the agreements. As of December 31, 2024, the Company has commitments to make a total of $ 13.2 million in purchases over the next one year . To date, the Company has met the minimum purchase commitments. | text | 13.2 | monetaryItemType | text: <entity> 13.2 </entity> <entity type> monetaryItemType </entity type> <context> Company’s behalf and cannot be used by their other customers, the Company is obligated to purchase these components. In addition, certain supplier agreements require the Company to make minimum annual purchases under the agreements. As of December 31, 2024, the Company has commitments to make a total of $ 13.2 million in purchases over the next one year . To date, the Company has met the minimum purchase commitments. </context> | us-gaap:PurchaseObligation |
As of December 31, 2024, the Company has entered into non-cancelable arrangements for subscription software services to make payments aggregating to $ 19.6 million over the next five years . | text | 19.6 | monetaryItemType | text: <entity> 19.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company has entered into non-cancelable arrangements for subscription software services to make payments aggregating to $ 19.6 million over the next five years . </context> | us-gaap:ContractualObligation |
The minimum commitments related to the Company's license arrangements aggregate to $ 14.6 million as of December 31, 2024 to be paid over the next 14 years. | text | 14.6 | monetaryItemType | text: <entity> 14.6 </entity> <entity type> monetaryItemType </entity type> <context> The minimum commitments related to the Company's license arrangements aggregate to $ 14.6 million as of December 31, 2024 to be paid over the next 14 years. </context> | us-gaap:ContractualObligation |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 12.6 | monetaryItemType | text: <entity> 12.6 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:OperatingLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 13.6 | monetaryItemType | text: <entity> 13.6 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:OperatingLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 13.1 | monetaryItemType | text: <entity> 13.1 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:OperatingLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:VariableLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:VariableLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:VariableLeaseCost |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:SubleaseIncome |
For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. | text | 0.5 | monetaryItemType | text: <entity> 0.5 </entity> <entity type> monetaryItemType </entity type> <context> For the years ended December 31, 2024, 2023 and 2022, the Company incurred $ 12.6 million, $ 13.6 million and $ 13.1 million, respectively, of operating lease costs and $ 0.5 million, $ 0.2 million and $ 0.4 million, respectively, of variable lease costs. The variable lease cost is comprised primarily of the Company’s proportionate share of operating expenses, property taxes and insurance and is classified as lease cost due to the Company’s election to not separate lease and non-lease components. The sublease income for the years ended December 31, 2024 and 2023 were $ 1.2 million and $ 0.5 million, respectively. </context> | us-gaap:SubleaseIncome |
Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. | text | 17.8 | monetaryItemType | text: <entity> 17.8 </entity> <entity type> monetaryItemType </entity type> <context> Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. </context> | us-gaap:OperatingLeasePayments |
Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. | text | 15.2 | monetaryItemType | text: <entity> 15.2 </entity> <entity type> monetaryItemType </entity type> <context> Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. </context> | us-gaap:OperatingLeasePayments |
Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. | text | 12.1 | monetaryItemType | text: <entity> 12.1 </entity> <entity type> monetaryItemType </entity type> <context> Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2024, 2023 and 2022 were $ 17.8 million, $ 15.2 million and $ 12.1 million, respectively, and were included in net cash used in operating activities in the Company’s consolidated statements of cash flows. </context> | us-gaap:OperatingLeasePayments |
For the year ended December 31, 2024, the Company incurred approximately $ 1.0 million costs associated with exit activities related to the lease expirations. | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> For the year ended December 31, 2024, the Company incurred approximately $ 1.0 million costs associated with exit activities related to the lease expirations. </context> | us-gaap:GainLossOnTerminationOfLease |
On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. | text | 31 | monetaryItemType | text: <entity> 31 </entity> <entity type> monetaryItemType </entity type> <context> On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. </context> | us-gaap:LossContingencyDamagesSoughtValue |
On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. | text | 25 | monetaryItemType | text: <entity> 25 </entity> <entity type> monetaryItemType </entity type> <context> On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. </context> | us-gaap:GainLossRelatedToLitigationSettlement |
On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. | text | 6 | monetaryItemType | text: <entity> 6 </entity> <entity type> monetaryItemType </entity type> <context> On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (“NanoString”) in the U.S. District Court for the District of Delaware alleging that NanoString’s GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the “GeoMx Action”). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company’s claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys’ fees) in relation to NanoString’s making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company’s motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString’s motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than $ 31 million in damages, consisting of approximately $ 25 million in lost profits and approximately $ 6 million in royalties. Post-trial motions, including the Company’s motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys’ fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court’s consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (“Bruker”) acquired certain assets and assumed certain liabilities of NanoString, including the litigation between 10x and NanoString, and the NanoString product lines at issue. Post-trial briefing is complete following supplementation by the parties. On December 23, 2024, the Court issued an opinion denying NanoString’s motion for judgement as a matter of law on invalidity, non-infringement and damages, and denied its request for a new trial. In that opinion, the Court granted the Company’s motion for permanent injunction, supplemental damages, and pre-judgment and post-judgment interest. Briefing with regard to the scope of the permanent injunction, supplemental damages, and pre- and post-judgment interest is ongoing. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of December 31, 2024. </context> | us-gaap:PaymentsForRoyalties |
A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString’s request conditioned upon NanoString posting a 2.3 million Euro security deposit. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> A hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString’s request conditioned upon NanoString posting a 2.3 million Euro security deposit. </context> | us-gaap:SecurityDeposit |
The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 1,200,000,000 shares of capital stock consisting of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock, and 100,000,000 shares of preferred stock. | text | 100000000 | sharesItemType | text: <entity> 100000000 </entity> <entity type> sharesItemType </entity type> <context> The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 1,200,000,000 shares of capital stock consisting of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock, and 100,000,000 shares of preferred stock. </context> | us-gaap:PreferredStockSharesAuthorized |
Following the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the Amended and Restated 2012 Stock Plan continue to be governed by their existing terms but no further awards may be granted under the Amended and Restated 2012 Stock Plan. As of December 31, 2024, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan which includes shares issuable upon the exercise of outstanding awards was 1,842,338 . | text | 1842338 | sharesItemType | text: <entity> 1842338 </entity> <entity type> sharesItemType </entity type> <context> Following the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the Amended and Restated 2012 Stock Plan continue to be governed by their existing terms but no further awards may be granted under the Amended and Restated 2012 Stock Plan. As of December 31, 2024, the number of shares of Class A common stock issuable under the Amended and Restated 2012 Stock Plan which includes shares issuable upon the exercise of outstanding awards was 1,842,338 . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The Omnibus Incentive Plan allows for the issuance of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”) or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of December 31, 2024, the number of shares of Class A common stock available for issuance under the 2019 Omnibus Incentive Plan was 9,245,631 shares issuable in connection with outstanding awards and 19,637,882 shares reserved for issuance in connection with grants of future awards. | text | 19637882 | sharesItemType | text: <entity> 19637882 </entity> <entity type> sharesItemType </entity type> <context> The Omnibus Incentive Plan allows for the issuance of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”) or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of December 31, 2024, the number of shares of Class A common stock available for issuance under the 2019 Omnibus Incentive Plan was 9,245,631 shares issuable in connection with outstanding awards and 19,637,882 shares reserved for issuance in connection with grants of future awards. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. | text | 11000000 | sharesItemType | text: <entity> 11000000 </entity> <entity type> sharesItemType </entity type> <context> The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. | text | 11000000 | sharesItemType | text: <entity> 11000000 </entity> <entity type> sharesItemType </entity type> <context> The number of shares of Class A common stock reserved for issuance under the 2019 Omnibus Incentive Plan at the time the 2019 Omnibus Incentive Plan was adopted in 2019 was 11,000,000 . The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5 % increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 33.67 | perShareItemType | text: <entity> 33.67 </entity> <entity type> perShareItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 32.95 | perShareItemType | text: <entity> 32.95 </entity> <entity type> perShareItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 12.3 | monetaryItemType | text: <entity> 12.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 78.0 | monetaryItemType | text: <entity> 78.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 89.5 | monetaryItemType | text: <entity> 89.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . | text | 19.5 | monetaryItemType | text: <entity> 19.5 </entity> <entity type> monetaryItemType </entity type> <context> The Company did not grant stock options during the year ended December 31, 2024. The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022 was $ 33.67 , and $ 32.95 per share, respectively. The total intrinsic value of stock options exercised was $ 12.3 million, $ 78.0 million and $ 89.5 million during the years ended December 31, 2024, 2023, and 2022, respectively. As of December 31, 2024, the total unrecognized stock-based compensation related to stock options was $ 19.5 million, which will be recognized over a weighted-average period of approximately two years . </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
As of December 31, 2024, the total unrecognized stock-based compensation related to RSUs was $ 194.4 million, which will be recognized over a weighted-average period of approximately three years . | text | 194.4 | monetaryItemType | text: <entity> 194.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the total unrecognized stock-based compensation related to RSUs was $ 194.4 million, which will be recognized over a weighted-average period of approximately three years . </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
In March 2024, the Company granted 219,168 performance stock units (“PSUs”) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company’s Compensation Committee of the Board of Directors as described below: | text | 219168 | sharesItemType | text: <entity> 219168 </entity> <entity type> sharesItemType </entity type> <context> In March 2024, the Company granted 219,168 performance stock units (“PSUs”) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company’s Compensation Committee of the Board of Directors as described below: </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
50 % of target PSUs earned will be based on the Company’s compound annual growth rate (CAGR) of the Company’s Revenue over a two-year performance period from January 1, 2024 to December 31, 2025. Holders may earn from 0 % to 175 % of the target amount of shares and earned PSUs will then be subject to service-based vesting; and | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> 50 % of target PSUs earned will be based on the Company’s compound annual growth rate (CAGR) of the Company’s Revenue over a two-year performance period from January 1, 2024 to December 31, 2025. Holders may earn from 0 % to 175 % of the target amount of shares and earned PSUs will then be subject to service-based vesting; and </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
50 % of target PSUs earned will be based on the relative Total Shareholder Return (TSR) of the Company’s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2024 to December 31, 2026. Depending on the results relative to the TSR market condition, the holders may earn from 0 % to 200 % of the target amount of shares which will vest at the end of the performance period. | text | 50 | percentItemType | text: <entity> 50 </entity> <entity type> percentItemType </entity type> <context> 50 % of target PSUs earned will be based on the relative Total Shareholder Return (TSR) of the Company’s common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2024 to December 31, 2026. Depending on the results relative to the TSR market condition, the holders may earn from 0 % to 200 % of the target amount of shares which will vest at the end of the performance period. </context> | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. | text | 37.43 | perShareItemType | text: <entity> 37.43 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. | text | 44.80 | perShareItemType | text: <entity> 44.80 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were $ 37.43 and $ 44.80 per share respectively. Stock-based compensation expense recognized for the PSUs relating to TSR components were approximately $ 1.3 million for the year ended December 31, 2024. The PSUs relating to CAGR components were not deemed probable of vesting as of December 31, 2024, and no expenses were recognized for 2024. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
In March 2023, the Company granted 172,842 performance restricted stock unit awards (“PSAs”) under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Compensation Committee of the Board of Directors. | text | 172842 | sharesItemType | text: <entity> 172842 </entity> <entity type> sharesItemType </entity type> <context> In March 2023, the Company granted 172,842 performance restricted stock unit awards (“PSAs”) under the 2019 Plan to certain members of management, which are subject to the achievement of certain escalating stock price thresholds established by the Company's Compensation Committee of the Board of Directors. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod |
The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. | text | 43.13 | perShareItemType | text: <entity> 43.13 </entity> <entity type> perShareItemType </entity type> <context> The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> The PSAs each vest in equal installments upon the achievement of escalating stock price thresholds of $ 72.14 , $ 96.19 and $ 120.24 respectively, calculated based on the volume-weighted average price per share of the Company’s Class A common stock over the immediately trailing 20 trading day period for each respective threshold. The escalating stock price thresholds can be met any time prior to the fifth anniversary of the date of grant. The vesting of the PSAs can also be triggered upon certain change in control events and achievement of certain change in control price thresholds, or in the event of death or disability. The weighted-average grant date fair value of the PSAs was $ 43.13 . Stock-based compensation expense recognized for these market-based awards was approximately $ 1.7 million and $ 5.1 million for the years ended December 31, 2024 and 2023, respectively. </context> | us-gaap:EmployeeBenefitsAndShareBasedCompensation |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.